Is Hims compounded semaglutide the same as Ozempic?

No. Ozempic is the FDA-approved branded semaglutide manufactured by Novo Nordisk under FDA-supervised cGMP standards. Hims compounded semaglutide is produced by a licensed compounding pharmacy without FDA-approval-level review of the specific compounded product. Compounded products are legal under sections 503A/503B of the FD&C Act but are a different regulatory category from branded drugs.

Did the FDA ban compounded semaglutide?

No, the FDA has not banned compounded semaglutide. However, the FDA declared the semaglutide shortage resolved in October 2024, which narrowed the legal basis for shortage-driven compounding. Patient-specific compounding (503A) is still legal for an individualized prescription. The FDA has issued multiple safety alerts about specific compounded products, particularly those using salt forms (semaglutide sodium, semaglutide acetate) that are not the same active ingredient as Ozempic.

How much cheaper is compounded semaglutide?

Compounded semaglutide programs typically advertise $200–$500/month versus roughly $1,350/month list price for Wegovy. After manufacturer coupons and pharmacy discounts, branded Wegovy can be $500–$1,000/month for cash-pay patients. The savings are real but reflect the lower oversight burden on the compounded version.

Has anyone been harmed by compounded semaglutide?

Yes. The FDA and state pharmacy boards have received reports of dosing errors (often resulting in severe hypoglycemia or pancreatitis), wrong-active-ingredient cases, and sterility issues. The 2024 FDA alerts cite specific hospitalization cases. Compounded injectables historically carry sterility risk that has caused fatal outbreaks (the 2012 NECC fungal meningitis outbreak killed 64 people). The cumulative case count for compounded semaglutide harm is non-zero but exact numbers are not publicly aggregated.

Is Hims operating legally?

As of May 2026, Hims has not faced FDA enforcement action over its compounded GLP-1 program. The legal pathway depends on Hims using either an FDA-registered 503B outsourcing facility or 503A patient-specific compounding. Hims has not consistently disclosed which tier supplies its program; that disclosure should be requested before signing up. The regulatory landscape is moving — Florida, Texas, and California have proposed legislation; the Outsourcing Facility Association v. FDA case continues; and FDA enforcement against bad-actor compounders is ongoing.

What should I ask my doctor before starting?

(1) Am I eligible for branded Wegovy or Zepbound through my insurance? (2) If I use a compounded version, which pharmacy is supplying it and is it 503A or 503B? (3) Is the active ingredient semaglutide base or a salt form (the latter is not FDA-approved)? (4) How is my dose being delivered — pre-filled pens or vials with my own draw? (5) What is the plan if I have side effects or need to stop?

Is Hims Compounded GLP-1 Safe? 2026 FDA Risks Explained

TL;DR

Hims sells compounded semaglutide and (in some plans) compounded liraglutide via licensed compounding pharmacies. Pricing is typically a fraction of Wegovy/Ozempic list price.
Compounded GLP-1s are not FDA-approved drugs. They are not equivalent to Wegovy or Ozempic in terms of FDA review, manufacturing oversight, or efficacy data.
The FDA has issued multiple warnings since 2024 about compounded semaglutide products containing salt forms (semaglutide sodium, semaglutide acetate) that are not the active ingredient in Ozempic/Wegovy.
Compounding is legal under federal law in two scenarios: when a drug is on the FDA Drug Shortage List (semaglutide was on this list 2022–2024), and for individualized patient-specific prescriptions. The shortage exemption ended for semaglutide in late 2024, narrowing the legal pathway.
Hims has not faced FDA enforcement specifically over compounded GLP-1s as of May 2026, but the regulatory landscape is moving fast. Read the disclosures Hims publishes before signing up.

What is a "compounded" medication?

Compounding is the practice of mixing customized medications by a licensed pharmacist for an individual patient. The legal framework lives in two sections of the Federal Food, Drug, and Cosmetic Act:

Section 503A — small pharmacies that compound for an identified individual patient based on a prescription. Lower regulatory oversight; not FDA-inspected like commercial drug manufacturers.
Section 503B — outsourcing facilities registered with the FDA that can produce in larger quantities. Higher oversight (cGMP standards, FDA inspection) but still not FDA-approval-level review.

Compounded medications skip the FDA new-drug approval pathway. There is no FDA review of safety, efficacy, or manufacturing consistency at the drug level — only the pharmacy's licensing and (for 503B) facility inspection.

Why Hims sells compounded semaglutide instead of Wegovy

Wegovy (the FDA-approved semaglutide product for chronic weight management) costs roughly $1,350/month at list price in the US, of which patients on cash typically pay $500–$1,000/month after manufacturer coupons. Compounded semaglutide programs, including Hims', advertise prices in the $200–$500/month range — a fraction of the branded product.

The legal cover for compounding semaglutide existed because semaglutide was placed on the FDA Drug Shortage List in 2022. Under federal law, compounding pharmacies can produce a drug that is on the shortage list to fill the gap, even if a branded version exists. That window remained open from 2022 through late 2024.

In October 2024, the FDA declared the semaglutide shortage resolved. The shortage-list exemption for compounding effectively closes when a drug is removed from the list, with a transition period for compounders to adjust. Compounded semaglutide is still sold, but the legal basis is now narrower — typically arguing patient-specific clinical needs rather than shortage. The 2024 Outsourcing Facility Association v. FDA litigation challenged FDA's removal of semaglutide from the shortage list; a federal court denied the request to vacate FDA's decision in early 2025.

The risks the FDA has flagged

Since 2023 the FDA has issued multiple safety alerts about compounded semaglutide products. Three categories of concern:

Wrong active ingredient. Some compounded products use semaglutide salt forms — semaglutide sodium, semaglutide acetate — that are not the same as the active pharmaceutical ingredient in Ozempic or Wegovy (semaglutide base). These salts are not FDA-approved for any use and have not been studied in humans for efficacy or safety. The FDA has explicitly warned compounders against using these forms.
Dosing errors. The FDA has received reports of patients overdosing on compounded semaglutide because dosing is delivered in vials (mL-based) rather than the pre-filled pens (mg-based) used for Wegovy/Ozempic. Some patients have been hospitalized for hypoglycemia, severe vomiting, or pancreatitis after dosing errors.
Sterility and contamination. 503A pharmacies are not subject to FDA cGMP inspection. Sterility failures in injectable compounded products have caused fatal contamination outbreaks historically (the 2012 NECC fungal meningitis outbreak killed 64 people). Compounded injectables, including semaglutide, carry sterility risk that branded GLP-1s do not.

What Hims says about its compounded program

Hims publishes disclosures stating that compounded medications are not FDA-approved and that the compounded products are made by licensed pharmacies on a patient-specific basis. The Hims program includes:

A medical evaluation by a licensed clinician via the platform.
Use of US-based licensed compounding pharmacies (501A and/or 503B facilities — Hims has not consistently disclosed which tier).
Patient-specific prescriptions.

Hims has not faced FDA enforcement specifically over its compounded GLP-1 program as of May 2026. That may change as the regulatory landscape evolves — the Outsourcing Facility Association litigation, ongoing FDA enforcement against bad-actor compounders, and pending state-level legislation in Florida, Texas, and California are all moving variables.

How to think about whether to use it

This is not medical advice. The decision depends on individual clinical context, financial reality, and risk tolerance. Three questions worth asking your prescribing clinician:

If you are eligible for branded Wegovy or Zepbound and your insurance covers it, compounded GLP-1 is harder to justify on a risk-benefit basis — the branded products have full FDA review, established sterility chains, and dosing devices designed to prevent error.
If you are not insurance-eligible and the choice is between compounded semaglutide via a reputable provider and no GLP-1 at all, the calculation changes. Some clinicians and patients reasonably conclude that supervised compounded GLP-1 is preferable to no treatment for severe obesity, even with the regulatory caveats.
If you are considering Hims, verify which compounding pharmacy is supplying the medication, ask whether the active ingredient is semaglutide base (not a salt form), and ensure your dosing is delivered in pre-filled pens or with explicit per-dose labeling.

Bottom line

Compounded GLP-1s are a legal but lower-oversight category of medication. They are not equivalent to FDA-approved Wegovy or Ozempic. The cost difference is real; so are the regulatory and safety differences. Anyone using a compounded GLP-1 — whether through Hims or any other telehealth provider — should understand they are accepting a different risk profile than they would with branded GLP-1s and should be supervised by a qualified clinician with access to their full medical history.

Is Hims Compounded GLP-1 Safe? An Evidence-Based 2026 Explainer